- $1.05bn
- $925.99m
- $7.64m
Annual income statement for Enovix, fiscal year end - January 1st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2022 January 2nd | 2023 December 31st | 2023 January 1st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 52 W | 52 W | 52 W |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 7.64 | 6.2 |
| Cost of Revenue | |||||
| Gross Profit | — | — | — | -55.4 | -17 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 16.5 | 21.9 | 69.5 | 238 | 138 |
| Operating Profit | -16.5 | -21.9 | -69.5 | -230 | -132 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -16.2 | -39.6 | -126 | -215 | -51.6 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -16.2 | -39.6 | -126 | -214 | -51.6 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -16.2 | -39.6 | -126 | -214 | -51.6 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -16.2 | -39.6 | -126 | -214 | -51.6 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.111 | -0.284 | -1.07 | -1.32 | -0.305 |
| Dividends per Share |